$RCUS
Arcus Biosciences, Inc.

2021 Q2 Form 10-Q Financial Statement

#000156459021041611 Filed on August 05, 2021

View on sec.gov

Income Statement

Concept 2021 Q2 2020 Q2
Revenue $9.461M $1.750M
YoY Change 440.63% 0.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $16.83M $11.43M
YoY Change 47.21% 93.4%
% of Gross Profit
Research & Development $68.77M $35.69M
YoY Change 92.67% 42.78%
% of Gross Profit
Depreciation & Amortization $820.0K $800.0K
YoY Change 2.5% 0.0%
% of Gross Profit
Operating Expenses $85.60M $47.13M
YoY Change 81.64% 52.46%
Operating Profit -$76.14M -$45.38M
YoY Change 67.79% 55.61%
Interest Expense $166.0K $300.0K
YoY Change -44.67% -71.96%
% of Operating Profit
Other Income/Expense, Net $166.0K $301.0K
YoY Change -44.85% -71.87%
Pretax Income -$75.97M -$45.07M
YoY Change 68.56% 60.45%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$75.97M -$45.07M
YoY Change 68.55% 60.46%
Net Earnings / Revenue -802.98% -2575.66%
Basic Earnings Per Share
Diluted Earnings Per Share -$1.089M -$928.1K
COMMON SHARES
Basic Shares Outstanding 48.56M
Diluted Shares Outstanding 48.56M

Balance Sheet

Concept 2021 Q2 2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $721.0M $462.5M
YoY Change 55.89% 106.11%
Cash & Equivalents $320.5M $285.2M
Short-Term Investments $400.5M $177.3M
Other Short-Term Assets $21.97M $8.700M
YoY Change 152.49% 163.64%
Inventory
Prepaid Expenses
Receivables $2.975M $500.0K
Other Receivables $0.00 $0.00
Total Short-Term Assets $746.0M $471.6M
YoY Change 58.18% 107.08%
LONG-TERM ASSETS
Property, Plant & Equipment $59.94M $8.264M
YoY Change 625.35% -20.25%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $84.10M
YoY Change
Other Assets $8.780M $1.323M
YoY Change 563.64% 314.73%
Total Long-Term Assets $152.8M $9.790M
YoY Change 1460.97% -12.91%
TOTAL ASSETS
Total Short-Term Assets $746.0M $471.6M
Total Long-Term Assets $152.8M $9.790M
Total Assets $898.8M $481.4M
YoY Change 86.7% 101.44%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $16.96M $12.05M
YoY Change 40.7% 392.32%
Accrued Expenses $9.706M $5.611M
YoY Change 72.98% -63.92%
Deferred Revenue $7.000M
YoY Change 0.0%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $130.4M $40.03M
YoY Change 225.72% 50.96%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $163.8M $693.0K
YoY Change 23543.29% -45.99%
Total Long-Term Liabilities $163.8M $693.0K
YoY Change 23543.29% -45.99%
TOTAL LIABILITIES
Total Short-Term Liabilities $130.4M $40.03M
Total Long-Term Liabilities $163.8M $693.0K
Total Liabilities $294.2M $52.68M
YoY Change 458.51% 24.45%
SHAREHOLDERS EQUITY
Retained Earnings -$278.2M
YoY Change 67.18%
Common Stock $6.000K
YoY Change 50.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $604.6M $428.7M
YoY Change
Total Liabilities & Shareholders Equity $898.8M $481.4M
YoY Change 86.7% 101.44%

Cashflow Statement

Concept 2021 Q2 2020 Q2
OPERATING ACTIVITIES
Net Income -$75.97M -$45.07M
YoY Change 68.55% 60.46%
Depreciation, Depletion And Amortization $820.0K $800.0K
YoY Change 2.5% 0.0%
Cash From Operating Activities -$74.01M -$23.90M
YoY Change 209.67% 20.71%
INVESTING ACTIVITIES
Capital Expenditures -$6.114M -$300.0K
YoY Change 1938.0% -50.0%
Acquisitions
YoY Change
Other Investing Activities $9.043M -$86.90M
YoY Change -110.41% -419.49%
Cash From Investing Activities $3.029M -$87.10M
YoY Change -103.48% -426.22%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.251M 328.9M
YoY Change -99.32% 54716.67%
NET CHANGE
Cash From Operating Activities -74.01M -23.90M
Cash From Investing Activities 3.029M -87.10M
Cash From Financing Activities 2.251M 328.9M
Net Change In Cash -68.73M 217.9M
YoY Change -131.54% 2805.33%
FREE CASH FLOW
Cash From Operating Activities -$74.01M -$23.90M
Capital Expenditures -$6.114M -$300.0K
Free Cash Flow -$67.90M -$23.60M
YoY Change 187.7% 22.92%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2021Q2 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
rcus:CollaborationMember
CY2020Q2 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
rcus:CollaborationMember
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
rcus:CollaborationMember
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
rcus:CollaborationMember
CY2021Q2 us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
CY2021Q2 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
us-gaap:OtherCurrentLiabilitiesMember
CY2021Q2 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
rcus:CollaborationMember
CY2020Q2 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
rcus:CollaborationMember
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
rcus:CollaborationMember
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
rcus:CollaborationMember
CY2021Q2 us-gaap Accounts Receivable Related Parties Current
AccountsReceivableRelatedPartiesCurrent
1324000
CY2020Q4 us-gaap Accounts Receivable Related Parties Current
AccountsReceivableRelatedPartiesCurrent
943000
dei Document Transition Report
DocumentTransitionReport
false
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Shell Company
EntityShellCompany
false
CY2021Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
71394037
dei Entity File Number
EntityFileNumber
001-38419
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-3898435
dei Entity Address Address Line1
EntityAddressAddressLine1
3928 Point Eden Way
dei Entity Address City Or Town
EntityAddressCityOrTown
Hayward
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94545
dei City Area Code
CityAreaCode
510
dei Local Phone Number
LocalPhoneNumber
694-6200
dei Security12b Title
Security12bTitle
Common Stock, Par Value $0.0001 Per Share
dei Security Exchange Name
SecurityExchangeName
NYSE
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
320482000
CY2021Q2 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
400530000
CY2021Q2 rcus Common Stock Shares Outstanding Includes Shares Issued But Subject To Vesting
CommonStockSharesOutstandingIncludesSharesIssuedButSubjectToVesting
1331269
CY2020Q4 rcus Common Stock Shares Outstanding Includes Shares Issued But Subject To Vesting
CommonStockSharesOutstandingIncludesSharesIssuedButSubjectToVesting
1422784
CY2021Q2 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
7711000
CY2020Q2 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
0
us-gaap Revenue From Related Parties
RevenueFromRelatedParties
15422000
us-gaap Revenue From Related Parties
RevenueFromRelatedParties
0
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
9461000
CY2020Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1750000
CY2020Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1750000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
18922000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3500000
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
68771000
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
35693000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
135158000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
58835000
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
16826000
CY2020Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11432000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
32647000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
18440000
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
85597000
CY2020Q2 us-gaap Operating Expenses
OperatingExpenses
47125000
us-gaap Operating Expenses
OperatingExpenses
167805000
us-gaap Operating Expenses
OperatingExpenses
77275000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-76136000
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-45375000
us-gaap Operating Income Loss
OperatingIncomeLoss
-148883000
us-gaap Operating Income Loss
OperatingIncomeLoss
-73775000
CY2021Q2 rcus Interest And Other Income Expense Nonoperating Net
InterestAndOtherIncomeExpenseNonoperatingNet
166000
CY2020Q2 rcus Interest And Other Income Expense Nonoperating Net
InterestAndOtherIncomeExpenseNonoperatingNet
301000
rcus Interest And Other Income Expense Nonoperating Net
InterestAndOtherIncomeExpenseNonoperatingNet
320000
rcus Interest And Other Income Expense Nonoperating Net
InterestAndOtherIncomeExpenseNonoperatingNet
948000
CY2020Q2 us-gaap Gain Loss On Sale Of Equity Investments
GainLossOnSaleOfEquityInvestments
131000
us-gaap Gain Loss On Sale Of Equity Investments
GainLossOnSaleOfEquityInvestments
613000
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-613000
CY2021Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
166000
CY2020Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
301000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
320000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
948000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-75970000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-45074000
us-gaap Net Income Loss
NetIncomeLoss
-148563000
us-gaap Net Income Loss
NetIncomeLoss
-72827000
CY2021Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-44000
CY2020Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-144000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-90000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
80000
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-76014000
CY2020Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-45218000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-148653000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-72747000
CY2021Q2 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-1.09
CY2020Q2 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.93
us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-2.17
us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-1.57
CY2021Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
69745297
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
48556843
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
68421086
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
46419724
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
163842000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
643000
CY2020Q1 rcus Stock Issued During Period Value Vesting Of Early Exercised Stock Option
StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOption
220000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3462000
CY2020Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
224000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-27753000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
140638000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
21629000
CY2020Q2 us-gaap Costs And Expenses Related Party
CostsAndExpensesRelatedParty
3762000
CY2020Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
326246000
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1751000
CY2020Q2 rcus Stock Issued During Period Value Vesting Of Early Exercised Stock Option
StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOption
216000
CY2020Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
607000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4470000
CY2020Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-144000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-45074000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
428710000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
502304000
CY2021Q1 rcus Stock Issued During Period Value Stock Options Exercised And Vesting Of Restricted Stock
StockIssuedDuringPeriodValueStockOptionsExercisedAndVestingOfRestrictedStock
1885000
CY2021Q1 rcus Stock Issued During Period Value Vesting Of Early Exercised Stock Option
StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOption
183000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
12761000
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-46000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-72593000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
664790000
CY2021Q2 rcus Stock Issued During Period Value Stock Options Exercised And Vesting Of Restricted Stock
StockIssuedDuringPeriodValueStockOptionsExercisedAndVestingOfRestrictedStock
843000
CY2021Q2 rcus Stock Issued During Period Value Vesting Of Early Exercised Stock Option
StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOption
175000
CY2021Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1394000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
13367000
CY2021Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-44000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-75970000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
604555000
us-gaap Profit Loss
ProfitLoss
-148563000
us-gaap Profit Loss
ProfitLoss
-72827000
us-gaap Share Based Compensation
ShareBasedCompensation
26128000
us-gaap Share Based Compensation
ShareBasedCompensation
7932000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1620000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1629000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
1117000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
294000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-1412000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
323000
us-gaap Increase Decrease In Contract With Customer Asset
IncreaseDecreaseInContractWithCustomerAsset
526000
us-gaap Increase Decrease In Contract With Customer Asset
IncreaseDecreaseInContractWithCustomerAsset
90000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-471000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
135000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-3569000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
6668000
rcus Increase Decrease In Accrued Research And Development Expenses
IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses
10449000
rcus Increase Decrease In Accrued Research And Development Expenses
IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses
9327000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
163000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
661000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-18922000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-3500000
rcus Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-1003000
rcus Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-560000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-2000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
310000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-140311000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-55215000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
370690000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
139689000
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
438733000
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
92134000
rcus Proceeds From Sale Of Short Term And Long Term Investments
ProceedsFromSaleOfShortTermAndLongTermInvestments
7500000
rcus Proceeds From Sale Of Short Term And Long Term Investments
ProceedsFromSaleOfShortTermAndLongTermInvestments
1003000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
9714000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
465000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
65829000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-47017000
rcus Proceeds From Issuance Of Common Stock From Related Party
ProceedsFromIssuanceOfCommonStockFromRelatedParty
220235000
rcus Proceeds From Issuance Of Common Stock From Related Party
ProceedsFromIssuanceOfCommonStockFromRelatedParty
56738000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
220235000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
326512000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
4122000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
3001000
rcus Repurchase Of Unvested Shares Of Stock
RepurchaseOfUnvestedSharesOfStock
6000
rcus Repurchase Of Unvested Shares Of Stock
RepurchaseOfUnvestedSharesOfStock
33000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
224351000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
329480000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
227248000
rcus Cash Paid For Amounts Included In Measurement Of Lease Liabilities
CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities
2000000
rcus Tenant Improvement Allowance Receivable Included In Other Current Assets
TenantImprovementAllowanceReceivableIncludedInOtherCurrentAssets
10598000
rcus Vesting Of Early Exercised Stock Options
VestingOfEarlyExercisedStockOptions
436000
rcus Unpaid Portion Of Financing Costs Included In Account Payable
UnpaidPortionOfFinancingCostsIncludedInAccountPayable
266000
rcus Unpaid Portion Of Deferred Financing Costs Included In Accounts Payable
UnpaidPortionOfDeferredFinancingCostsIncludedInAccountsPayable
316000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
5804000
rcus Vesting Of Early Exercised Stock Options
VestingOfEarlyExercisedStockOptions
358000
us-gaap Nature Of Operations
NatureOfOperations
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Note </span><span style="color:#000000;">1. </span>Organization </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Description of Business </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arcus Biosciences, Inc. (the Company) is a clinical-stage biopharmaceutical company focused on creating best-in-class cancer therapies. The Company’s initial focus has been on well-characterized biological pathways with significant scientific data supporting their importance. Since its inception in 2015, the Company has built a robust and highly efficient drug discovery capability to create highly differentiated small molecules, which the Company is developing in combination with its in-licensed monoclonal antibodies through rationally designed, indication-specific clinical trial designs. The Company currently has five investigational products in clinical development: domvanalimab (formerly referred to as AB154), etrumadenant (formerly referred to as AB928), quemliclustat (formerly referred to as AB680), zimberelimab (formerly referred to as AB122), and AB308.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Liquidity and Capital Resources</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of June 30, 2021, the Company had cash and investments of $805.1 million, which are cash, cash equivalents, and investments in marketable securities, which the Company believes will be sufficient to fund its planned operations for a period of at least twelve months following the date of filing of this report.</p>
rcus Number Of Investigational Product
NumberOfInvestigationalProduct
5
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the Company’s condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, as well as related disclosures of contingent assets and liabilities. Estimates were used to determine the standalone selling price of performance obligations and the timing of revenue recognition, the value of stock-based awards and other issuances, accruals for research and development costs, useful lives of long-lived assets, and uncertain tax positions. Actual results could differ materially from the Company’s estimates. </p>
CY2020 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
CY2020 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
320482000
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
285185000
CY2021Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
3005000
CY2020Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
203000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
323487000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
285388000
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentration of Credit Risk</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents, short-term and long-term investments are financial instruments that potentially subject the Company to concentrations of credit risk. The Company invests in money market funds, treasury bills and notes, government bonds, commercial paper and corporate notes. The Company limits its credit risk associated with cash equivalents, short-term and long-term investments by placing them with banks and institutions it believes are credit worthy and in highly rated investments. </p>
CY2021Q2 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2020Q4 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2021Q2 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2020Q4 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2021Q2 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2020Q4 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2021Q2 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2020Q4 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2020 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2020Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
173415000
CY2021Q2 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
400530000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2020 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2020Q4 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
555231000
CY2021Q2 us-gaap Available For Sale Securities Noncurrent
AvailableForSaleSecuritiesNoncurrent
84096000
CY2020Q4 us-gaap Available For Sale Securities Noncurrent
AvailableForSaleSecuritiesNoncurrent
6440000
CY2021Q2 rcus Cash Cash Equivalents And Available For Sale Investments
CashCashEquivalentsAndAvailableForSaleInvestments
805108000
CY2020Q4 rcus Cash Cash Equivalents And Available For Sale Investments
CashCashEquivalentsAndAvailableForSaleInvestments
735086000
us-gaap Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax
ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
0
CY2020 us-gaap Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax
ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
0
CY2021Q2 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
805154000
CY2021Q2 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
50000
CY2021Q2 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
320482000
CY2021Q2 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
96000
CY2021Q2 us-gaap Available For Sale Securities
AvailableForSaleSecurities
805108000
CY2020Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
735042000
CY2020Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
57000
CY2020Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
13000
CY2020Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
735086000
CY2021Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
8599000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
8632000
CY2021Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
756000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
295000
CY2021Q2 rcus Other Accrued Liabilities
OtherAccruedLiabilities
351000
CY2020Q4 rcus Other Accrued Liabilities
OtherAccruedLiabilities
616000
CY2021Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9706000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9543000
us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
the lease amendment and replaced by two options to extend the lease term for the entire 150,753 square feet then under lease in the Hayward premises for a period of eight years each.
CY2021Q2 rcus Operating Lease Option To Extend Lease Term
OperatingLeaseOptionToExtendLeaseTerm
P8Y
CY2021Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P10Y6M
CY2021Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.052
CY2021Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
1500000
us-gaap Operating Lease Cost
OperatingLeaseCost
2600000
CY2020Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
500000
us-gaap Operating Lease Cost
OperatingLeaseCost
1100000
CY2021Q2 us-gaap Short Term Lease Cost
ShortTermLeaseCost
100000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
300000
CY2021Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
36100000
CY2021Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
52200000
CY2021Q2 rcus Lessee Operating Lease Tenant Improvement Allowance Receivable
LesseeOperatingLeaseTenantImprovementAllowanceReceivable
11600000
rcus Lessee Operating Lease Tenant Improvement Allowance Receivable Expected Period
LesseeOperatingLeaseTenantImprovementAllowanceReceivableExpectedPeriod
P1Y
CY2021Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2500000
CY2021Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
49700000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
2233000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
5722000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
5908000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
6101000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
6302000
CY2021Q2 rcus Lessee Operating Lease Liability Payments Due Thereafter
LesseeOperatingLeaseLiabilityPaymentsDueThereafter
42489000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
68755000
CY2021Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
16577000
CY2021Q2 rcus Lessee Operating Lease Tenant Improvement Allowance Receivable
LesseeOperatingLeaseTenantImprovementAllowanceReceivable
11577000
CY2021Q2 rcus Operating Lease Liability Net Of Tenant Improvement Allowances Receivable
OperatingLeaseLiabilityNetOfTenantImprovementAllowancesReceivable
40601000
CY2021Q2 rcus Tenant Improvement Allowance Expected To Be Received In Less Than One Year Net Of Current Portion Of Lease Liability
TenantImprovementAllowanceExpectedToBeReceivedInLessThanOneYearNetOfCurrentPortionOfLeaseLiability
9140000
CY2021Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
49741000
us-gaap Lessee Operating Lease Lease Not Yet Commenced Description
LesseeOperatingLeaseLeaseNotYetCommencedDescription
Total undiscounted future minimum lease payments do not include approximately $90.3 million and $5.3 million, respectively, related to the Company’s Brisbane lease and its additional space in Hayward, neither of which have yet commenced.
CY2021Q2 us-gaap Security Deposit
SecurityDeposit
3000000.0
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
9461000
CY2020Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1750000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
18922000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3500000
CY2021Q2 us-gaap Deferred Revenue Revenue Recognized1
DeferredRevenueRevenueRecognized1
9461000
CY2020Q2 us-gaap Deferred Revenue Revenue Recognized1
DeferredRevenueRevenueRecognized1
1750000
us-gaap Deferred Revenue Revenue Recognized1
DeferredRevenueRevenueRecognized1
18922000
us-gaap Deferred Revenue Revenue Recognized1
DeferredRevenueRevenueRecognized1
3500000
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
13367000
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4470000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
26128000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7932000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-75970000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-45074000
CY2021Q2 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
71094199
CY2020Q2 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
50153160
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
69792730
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
48053186
CY2021Q2 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
1348902
CY2020Q2 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
1596317
us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
1371644
us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
1633462
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
68421086
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
46419724
CY2021Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.09
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.93
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.17
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.57
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
15339497
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9429282

Files In Submission

Name View Source Status
0001564590-21-041611-index-headers.html Edgar Link pending
0001564590-21-041611-index.html Edgar Link pending
0001564590-21-041611.txt Edgar Link pending
0001564590-21-041611-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
rcus-10q_20210630.htm Edgar Link pending
rcus-10q_20210630_htm.xml Edgar Link completed
rcus-20210630.xsd Edgar Link pending
rcus-20210630_cal.xml Edgar Link unprocessable
rcus-20210630_def.xml Edgar Link unprocessable
rcus-20210630_lab.xml Edgar Link unprocessable
rcus-20210630_pre.xml Edgar Link unprocessable
rcus-ex102_6.htm Edgar Link pending
rcus-ex103_156.htm Edgar Link pending
rcus-ex311_7.htm Edgar Link pending
rcus-ex312_10.htm Edgar Link pending
rcus-ex321_9.htm Edgar Link pending
rcus-ex322_8.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending